Trial Profile

A clinical study for treatment of psoriasis with CYPS317

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2026 According to a FibroBiologics media release, the company anticipate IND clearance for the treatment of psoriasis with CYPS317 in the fourth quarter of 2026.
24 Feb 2026 According to a FibroBiologics media release, company received IND clearance for the treatment of psoriasis with CYPS317, in the first half of 2026.
31 Dec 2025 According to a FibroBiologics media release, the company announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical trials of CYPS317 for the treatment of moderate to severe psoriasis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com